Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
If approved by the FDA, SP-102 (SEMDEXA) will be available in a pre-filled syringe formulation. It will be administered as an epidural injection for sciatica treatment.Semnur Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company (NASDAQ:SCLX), and Denali Capital Acquisition Corp. (NASDAQ:DECA), a special purpose acquisition company, signed a letter of intent for a proposed business combination.
Scilex Holding Company (納斯達克:SCLX)全資子公司Semnur Pharmaceuticals Inc.和Denali Capital Acquisition Corp. (納斯達克:DECA)，一家特殊目的收購公司，簽署了股權諒解備忘錄，計劃進行業務合併。
The deal provides for a pre-transaction equity value of Semnur up to $2 billion, with expected gross proceeds of up to $40 million depending on the number of SPAC shares redeemed before the business combination is completed.
本次交易將爲Semnur提供達20億美元的交易前股權價值，預計募集可達4000萬美元的淨收益，具體額度取決於交易完成前的SPAC（特殊目的收購公司）股份贖回數量。
Semnur is a clinical late-stage specialty pharmaceutical company focused on developing and commercializing novel non-opioid pain therapies. Semnur's lead program, SP-102 (SEMDEXA), is the first non-opioid novel injectable corticosteroid gel formulation for moderate to severe chronic radicular pain/sciatica, containing no preservatives, surfactants, solvents, or particulates.
Semnur是一家專注於開發和商業化新型非阿片類疼痛治療藥物的臨床後期專業藥物公司。其主要項目SP-102（SEMDEXA）是一種針對中重度慢性根性疼痛/坐骨神經痛的首個非阿片類新型可注射的皮質激素凝膠製劑，不含防腐劑、表面活性劑、溶劑或微粒。
If approved by the FDA, SP-102 (SEMDEXA) will be available in a pre-filled syringe formulation. It will be administered as an epidural injection for sciatica treatment.
如果獲得FDA批准，SP-102（SEMDEXA）將以預充注射器的形式提供，並作爲腰麻神經根治療的一種注射劑治療坐骨神經痛。
SP-102 completed a Phase 3 trial, meeting primary and key secondary endpoints. The treatment decreased pain intensity for over a month in sciatica patients. It resulted in statistically significant and clinically meaningful improvement in the disability index score while maintaining safety comparable to placebo.
SP-102完成了III期試驗，並達到了主要和關鍵次要終點。該療法可以在坐骨神經痛患者中減輕一週以上的疼痛強度，並在維持與安慰劑相當的安全性的同時，導致了在殘疾指數得分上具有統計學上顯著和臨床意義的改善。
Sciatica happens when irritation, inflammation, pinching, or compression affects one or more nerves that run down your lower back and into the legs.
坐骨神經痛是一種神經受到刺激、炎症、擠壓或壓迫而影響下背部並延伸至腿部的疾病。
The parties anticipate seeking approval from the SPAC's shareholders in the second half of 2024.
雙方預計將在2024年下半年尋求SPAC股東的批准。
Per Syneos Health Consulting, peak sales potential is projected to be up to $3.6 billion annually five years post-launch.
據Syneos Health Consulting稱，五年後，該產品達到峯值銷售潛力高達每年36億美元。
In the U.S., more than 30 million people live with low back and radicular pain.
在美國，有超過3000萬人患有腰部和根性疼痛。
According to a proprietary study by Syneos Health, the overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered.
依據Syneos Health的專有研究，美國用於硬膜外阻滯類固醇注射（ESI）的總估計手術數量約爲1210萬例，涵蓋所有醫療保險和私人保險的患者，其中腰椎神經根或坐骨神經痛的手術佔所有ESI的88%。
Price Action: SCLX shares are up 5.18% at $2.02 at last check Wednesday.
截至上週三最後一次查詢，SCLX的股價上漲5.18%，至每股2.02美元。
- Marjorie Taylor Greene Buys Cybersecurity Stock Owned By Nancy Pelosi: Why Trade Could Draw Red Flags
- Marjorie Taylor Greene購買了南希·佩洛西擁有的網絡安全概念股票:爲什麼這筆交易可能引起關注
